Prevision Medicine, a transformative precision oncology startup, today announced it has successfully raised $5.4 million in its Seed round. The funding will accelerate the commercialization of its groundbreaking functional precision medicine test for hematological malignancies and solid tumors. The round was led by Swiss-based early-stage venture capital firm ACE Ventures. The strong investor syndicate highlights confidence in Prevision Medicine’s approach and included participation from GoHub Ventures, SICTIC, and prominent angel investors dedicated to advancing oncology and precision medicine.
Functional testing represents the next frontier in precision oncology. Prevision Medicine’s single-cell platform evaluates a patient’s living, tumor-derived cells against an extensive treatment library. By measuring direct cellular responses, the platform delivers actionable, personalized evidence that outperforms cohort-based treatment strategies in oncology. Backed by published clinical evidence, PrevisionOne helps support strategies for improved outcomes. “Prevision Medicine is a pioneer in establishing functional precision medicine in the clinic, offering new hope for patients with cancer.” says Philip Zimmermann, CEO of Prevision Medicine.
Capital deployment will drive key regulatory clearances and reimbursement coverage to make the test accessible to every patient. The capital will simultaneously fuel operational expansion across Europe, positioning the company to fulfill accelerating clinical adoption.
